

Understanding diabetic retinopathy

PU MingLiang

Department of Anatomy, School of Basic Medical Sciences, Peking University, Beijing 100191, China

Received June 2, 2015

Citation: Pu ML. Diabetic retinopathy special edition. *Sci China Life Sci*, 2015, 58: 519–520, doi: 10.1007/s11427-015-4890-8

A recent survey shows that diabetes affect 92.4 million people in mainland China [1], among which 16.9 million have diabetic retinopathy (DR) [2]. DR is one of the major causes of blindness in the working age population in both developing and developed countries. Although the exact mechanism by which diabetes causes retinopathy remains elusive, several hypotheses have been postulated to explain pathogenesis of the disease. Here we invited five groups of scientists and clinicians to share their recent discoveries and expert opinions in molecular biology, pathophysiology, genetics, and epigenetics of DR.

Retinal angiogenesis is a hallmark of ischemic retinopathy in DR. Exchange proteins directly activated by cAMP (Epacs, namely *Epac1* and *Epac2*) are important cAMP mediators that play crucial roles in maintenance of endothelial barrier and neuronal functions. However, functional roles of *Epac1* and *Epac2* remain to be determined. By transient occlusion of middle cerebral artery on *Epac1*- and *Epac2*-deficient mice, Liu and colleagues [3] demonstrated that *Epac2*^{-/-} ipsilateral retinas showed more neuronal cell loss in ganglion cell layer, increased retinal thickness and stronger immunostaining of AQP4, GFAP, and Prx6 than those of *Epac2*^{+/+}. Whereas *Epac1*^{-/-} ipsilateral retinae displayed similar pathology as those in *Epac1*^{+/+} mice. Together, they demonstrated that *Epac2*-deficiency led to more severe ischemic retinopathy after the injury. On the other hand, the apelin and apelin receptor (APJ) system is known to cause endothelium-dependent vasodilatation and to be involved in angiogenesis. Microglial cells are major components of the immune system in the retina. Diabetic injury

triggers these cells to release inflammatory cytotoxins that lead to neuronal and vascular cell death and develop diabetic retinopathy. However, it remains to be demonstrated if the activation of the inflammatory cytokines could be stimulated by apelin. Chen and colleagues [4] demonstrated that inflammatory cytokines secretion can be regulated by apelin stimulation. DR has a complex pathology that involves the vasculature of the inner retina and breakdown of the blood-retinal barrier. Barber [5] provided extensive evidence that DR is not only a vascular disease but also has a neurodegenerative component and that essentially all types of cells in the retina are affected, leading to chronic loss of visual function. Barber summarized recent developments in research towards understanding the complexities of retinal neurodegeneration occurring in DR, with neuronal loss, edema, glial cell reactivity and oxidative stress often observed. Indeed, in agreement with Barber's postulation, Zhu and coworkers [6] provided clinical evidence that type 2 diabetic patients without clinical evidence of diabetic retinopathy showed significantly decreased superior macular ganglion cell complex thicknesses in diabetic cases but no significant peripapillary retinal nerve fiber layer thickness changes were observed. The contrast sensitivities at all space frequencies were significantly different between diabetic patients and controls. In the diabetic group, average superior ganglion cell complex thicknesses positively correlated with both contrast sensitivities at high spatial frequencies and P50 amplitudes. These results suggest that ganglion cell complex thickness and visual function changes could be observed in diabetic subjects before the onset of any significant diabetic retinopathy. Despite cutting edge research in the field, how retina and its vasculature are damaged by the diabetic milieu remains to be explored.

email: mpu@bjmu.edu.cn

Kowluru and Mishra [7] suggested that the environmental factors, life style or disease process can also bring in modifications in the DNA, and these epigenetic modifications either silence or activate a gene without altering the DNA sequence. They discussed that diabetic environment regulates a number of genes in the retina, and a large body of evidence has shown that it also facilitates epigenetic modifications. Together, with epigenetic modifications taking an important place in diabetic retinopathy, they emphasize that it is now critical to investigate these epigenetic modifications, and understand their impact on this slowly progressed retinal disease.

Together, these results of laboratory and clinical investigations and expert opinions help us to better understand pathogenesis of DR.

This work was supported by grants from National Basic Research Program of China (973 Program, 2011CB510206).

- 1 Wang B, Wang F, Zhang Y, Zhao SH, Zhao WJ, Yan SL, Wang YG. Effects of RAS inhibitors on diabetic retinopathy: a systematic review and meta-analysis. *N Engl J Med*, 2010, 362: 1090–1101
- 2 Liu L, Wu X, Liu L, Geng J, Yuan Z, Shan Z, Chen L. Prevalence of diabetic retinopathy in mainland China: a meta-analysis. *PLoS One*, 2012, 7: e45264
- 3 Liu J, Yeung PKK, Cheng L, Lo ACY, Chung SSM, Chung SK. *Epac2*-deficiency leads to more severe retinal swelling, glial reactivity and oxidative stress in transient middle cerebral artery occlusion induced ischemic retinopathy. *Sci China Life Sci*, 2015, 58: 521–530
- 4 Chen L, Tao Y, Jiang YR. Apelin activates the expression of inflammatory cytokines in microglial BV2 cells via PI-3K/Akt and MEK/Erk pathways. *Sci China Life Sci*, 2015, 58: 531–540
- 5 Barber AJ. Diabetic retinopathy: recent advances towards understanding neurodegeneration and vision loss. *Sci China Life Sci*, 2015, 58: 541–549
- 6 Zhu TP, Ma J, Li YH, Zhang Z. Association between retinal neuronal degeneration and visual function impairment in type 2 diabetic patients without diabetic retinopathy. *Sci China Life Sci*, 2015, 58: 550–555
- 7 Kowluru RA, Mishra M. Contribution of epigenetics in diabetic retinopathy. *Sci China Life Sci*, 2015, 58: 556–563

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.



Biographical Sketch

Pu MingLiang, Ph.D., Professor, School of Basic Medical Sciences, Peking University. He received his doctoral degree in physiological optics in 1990 from the University of Alabama at Birmingham. His research interests include morphological characteristics and physiological properties of retinal ganglion cells, retinal visual and non-visual information processing, retinal neurocircuitry remodeling under different retinal disease conditions, gene therapy for visual function restoration, and affective visual information processing. He received NIH RO1 grant from USA and grants from National Natural Science Foundation of China, National Basic Research Program of China (973 Program) and National High Technology Research and Development Program of China (863 Program) from Ministry of Science and Technology. He published more than 30 research articles in top international journals, including *Science*, *Nature Neuroscience*, *Neuron*, *Neuropsychopharmacology*, and *Journal of Neuroscience*.